JP2008531734A5 - - Google Patents

Download PDF

Info

Publication number
JP2008531734A5
JP2008531734A5 JP2007558320A JP2007558320A JP2008531734A5 JP 2008531734 A5 JP2008531734 A5 JP 2008531734A5 JP 2007558320 A JP2007558320 A JP 2007558320A JP 2007558320 A JP2007558320 A JP 2007558320A JP 2008531734 A5 JP2008531734 A5 JP 2008531734A5
Authority
JP
Japan
Prior art keywords
compound
formula
compound according
substituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007558320A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008531734A (ja
JP5167473B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/007865 external-priority patent/WO2006094269A2/en
Publication of JP2008531734A publication Critical patent/JP2008531734A/ja
Publication of JP2008531734A5 publication Critical patent/JP2008531734A5/ja
Application granted granted Critical
Publication of JP5167473B2 publication Critical patent/JP5167473B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007558320A 2005-03-03 2006-03-03 抗血管新生化合物 Expired - Fee Related JP5167473B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US65865405P 2005-03-03 2005-03-03
US60/658,654 2005-03-03
US67708905P 2005-05-02 2005-05-02
US60/677,089 2005-05-02
PCT/US2006/007865 WO2006094269A2 (en) 2005-03-03 2006-03-03 Anti-angiogenic compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012228959A Division JP2013056895A (ja) 2005-03-03 2012-10-16 抗血管新生化合物

Publications (3)

Publication Number Publication Date
JP2008531734A JP2008531734A (ja) 2008-08-14
JP2008531734A5 true JP2008531734A5 (enExample) 2011-03-03
JP5167473B2 JP5167473B2 (ja) 2013-03-21

Family

ID=36941895

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007558320A Expired - Fee Related JP5167473B2 (ja) 2005-03-03 2006-03-03 抗血管新生化合物
JP2012228959A Pending JP2013056895A (ja) 2005-03-03 2012-10-16 抗血管新生化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012228959A Pending JP2013056895A (ja) 2005-03-03 2012-10-16 抗血管新生化合物

Country Status (6)

Country Link
US (3) US20080152660A1 (enExample)
EP (2) EP1853294A4 (enExample)
JP (2) JP5167473B2 (enExample)
KR (1) KR101373140B1 (enExample)
CA (1) CA2598833A1 (enExample)
WO (1) WO2006094269A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003059251A2 (en) * 2001-10-22 2003-07-24 The Scripps Research Institute Antibody targeting compounds
EP1853294A4 (en) * 2005-03-03 2010-01-27 Covx Technologies Ireland Ltd ANTIANGIOGENIC COMPOUNDS
AU2011254001B2 (en) * 2007-01-05 2012-08-02 Covx Technologies Ireland Limited Glucagon-like protein-1 receptor (GLP-1R) agonist compounds
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
US8293714B2 (en) * 2008-05-05 2012-10-23 Covx Technology Ireland, Ltd. Anti-angiogenic compounds
WO2009158668A1 (en) 2008-06-26 2009-12-30 Prolynx Llc Prodrugs and drug-macromolecule conjugates having controlled drug release rates
WO2010093706A2 (en) * 2009-02-10 2010-08-19 The Scripps Research Institute Chemically programmed vaccination
US20120189635A1 (en) 2009-07-29 2012-07-26 Regeneron Pharmaceuticals, Inc. Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2)
US8980268B2 (en) 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
WO2011094671A2 (en) * 2010-01-29 2011-08-04 The Uab Research Foundation N-terminally conjugated polypeptides for targeted therapy and diagnosis
US20130064838A1 (en) 2010-05-14 2013-03-14 Amgen Inc. Enhanced death receptor agonists
JP5913307B2 (ja) 2010-07-12 2016-04-27 コヴェックス・テクノロジーズ・アイルランド・リミテッド 多機能性抗体複合体
WO2012059873A2 (en) 2010-11-05 2012-05-10 Covx Technologies Ireland, Ltd. Anti-diabetic compounds
CA2822481A1 (en) 2011-01-03 2012-07-12 F. Hoffmann-La Roche Ag A pharmaceutical composition of a complex of an anti-dig antibody and digoxigenin that is conjugated to a peptide
TWI589592B (zh) 2011-11-17 2017-07-01 輝瑞股份有限公司 胞毒性肽類以及其抗體藥物共軛體
EP2793950A2 (en) * 2011-12-20 2014-10-29 Pfizer Inc Improved processes for preparing peptide conjugates and linkers
AU2012356219B2 (en) * 2011-12-22 2016-03-31 Covx Technologies Ireland Limited Anti-diabetic compounds
EP3539982B1 (en) 2011-12-23 2025-02-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
JP6413127B2 (ja) 2012-01-09 2018-10-31 コヴェックス・テクノロジーズ・アイルランド・リミテッド 変異抗体およびそのコンジュゲーション
MX350202B (es) 2012-03-28 2017-08-30 Amgen Inc Combinaciones de agonistas de receptores de muerte 5 (dr5).
ES2656298T3 (es) 2012-11-05 2018-02-26 Pfizer Inc. Análogos de ayustoestatina
CA2890571A1 (en) 2012-11-07 2014-05-15 Kenneth G. Geles Anti-notch3 antibodies and antibody-drug conjugates
CA2937731C (en) 2014-01-27 2019-09-24 Pfizer Inc. Bifunctional cytotoxic agents
WO2016110662A1 (en) * 2015-01-09 2016-07-14 Ipsen Bioinnovation Limited Cationic neurotoxins
WO2016151432A1 (en) 2015-03-20 2016-09-29 Pfizer Inc. Bifunctional cytotoxic agents containing the cti pharmacophore
EP3349795B1 (en) * 2015-09-17 2021-03-17 The Scripps Research Institute Dual variable domain immunoconjugates and uses thereof
US10689458B2 (en) 2015-11-30 2020-06-23 Pfizer Inc. Site specific HER2 antibody drug conjugates
WO2017134547A1 (en) 2016-02-01 2017-08-10 Pfizer Inc. Tubulysin analogs and methods for their preparation
ES3066090T3 (en) 2017-04-28 2026-05-11 Ajinomoto Co Inc Compound having substance that has affinity for soluble protein, cleavable moiety, and reactive group, or salt thereof
US11364303B2 (en) 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
CN108066285B (zh) * 2017-11-30 2019-06-07 江南大学 一种肝靶向共输送基因/药物的整合纳米系统及制备方法
US20250312472A1 (en) * 2022-04-29 2025-10-09 University Of Florida Research Foundation, Incorporated Antibody compounds with reactive cysteine and related antibody drug conjugates

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3719667A (en) * 1970-08-24 1973-03-06 Lilly Co Eli Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters
US3840556A (en) * 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5216132A (en) 1990-01-12 1993-06-01 Protein Design Labs, Inc. Soluble t-cell antigen receptor chimeric antigens
DE69126871T2 (de) 1990-04-06 1998-03-12 Jolla Cancer Res Found Verfahren und verbindung zur behandlung von thrombose
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US6080840A (en) * 1992-01-17 2000-06-27 Slanetz; Alfred E. Soluble T cell receptors
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US5733757A (en) 1995-12-15 1998-03-31 The Scripps Research Institute Aldolase catalytic antibody
US5739277A (en) * 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
CA2233060A1 (en) * 1995-09-26 1997-04-03 University Of Washington Glycoprotein b of the rfhv/kshv subfamily of herpes viruses
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
US5932545A (en) * 1997-03-17 1999-08-03 Abbott Laboratories Antiangiogenic drug to treat cancer, arthritis and retinopathy
GB9722131D0 (en) * 1997-10-20 1997-12-17 Medical Res Council Method
US6326176B1 (en) 1997-12-18 2001-12-04 The Scripps Research Institute Aldol condensations by catalytic antibodies
US6716963B1 (en) * 1998-05-22 2004-04-06 Abbott Laboratories Peptide antiangiogenic drugs
US6774211B1 (en) * 1998-05-22 2004-08-10 Abbott Laboratories Peptide antiangiogenic drugs
JP3753612B2 (ja) 1998-05-22 2006-03-08 アボット・ラボラトリーズ 抗血管新生作用を有するペプチド医薬
JP2003516121A (ja) 1999-09-27 2003-05-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 不可逆的に結合するエンジニアリング抗体
US6294374B1 (en) 1999-10-08 2001-09-25 The Scripps Research Institute Use of catalytic antibodies for synthesizing epothilone
CO5261544A1 (es) 1999-11-22 2003-03-31 Abbott Lab Peptidos n-alquilados que tienen actividad antiangiogenica
DK1232183T3 (da) 1999-11-22 2006-05-29 Abbott Lab Peptider, som har antiangiogen aktivitet
US6753408B1 (en) * 1999-11-22 2004-06-22 Fortuna Haviv Peptides having antiangiogenic activity
CA2391606A1 (en) * 1999-11-24 2001-05-31 The Liposome Company, Inc. Modular targeted liposomal delivery system
US20020183242A1 (en) * 2001-04-11 2002-12-05 Jack Henkin Peptide antiangiogenic drugs
AU2002319402B2 (en) 2001-06-28 2008-09-11 Domantis Limited Dual-specific ligand and its use
US20030045477A1 (en) * 2001-07-26 2003-03-06 Fortuna Haviv Peptides having antiangiogenic activity
WO2003059251A2 (en) * 2001-10-22 2003-07-24 The Scripps Research Institute Antibody targeting compounds
EP1600459A3 (en) 2002-06-28 2005-12-07 Domantis Limited Ligand
JP2006523090A (ja) 2002-12-27 2006-10-12 ドマンティス リミテッド リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体
WO2004091484A2 (en) * 2003-04-07 2004-10-28 Board Of Regents, The University Of Texas System Use of orsaponin [3beta, 16beta, 17 alpha-trihydroxycholost-5-en­22-one 16-0-(2-0-4-methoxybenzoyl-beta-d-xylopyranosyl)-(1->3)-(2-0­acetyl-alpha-l-arabinopyranoside)] or osw-1 and its derivatives for cancer therapeutics
WO2004091542A2 (en) * 2003-04-15 2004-10-28 Covx Pharmaceuticals, Inc. Nitrogen containing integrin targeting compounds
EP1853294A4 (en) * 2005-03-03 2010-01-27 Covx Technologies Ireland Ltd ANTIANGIOGENIC COMPOUNDS

Similar Documents

Publication Publication Date Title
JP2011500769A5 (enExample)
EP3130607A3 (en) Muc1* antibodies
JP2006520339A5 (enExample)
DE602006006200D1 (de) Antikörper gegen 25-hydroxyvitamin d
JP2010536766A5 (enExample)
JP2007269812A5 (enExample)
JP2009541403A5 (enExample)
EP2586842A3 (fr) Fluide de transfert de chaleur
JP2016537478A5 (enExample)
JP2013500371A5 (enExample)
WO2005016115A3 (en) Biosensors utilizing dendrimer-immobilized ligands and their use thereof
JP2009541415A5 (enExample)
JP2009013167A5 (ja) 有機金属錯体、発光材料、発光素子、及び発光装置
JP2011526313A5 (enExample)
WO2009052400A8 (en) Antibodies that bind to mammalian ngal and uses thereof
JP2010519270A5 (enExample)
WO2012041837A3 (de) Verfahren zur herstellung höherer hydridosilanverbindungen
JP2006527780A5 (enExample)
WO2008098917A3 (en) Novel antibodies against igf-ir
JP2010500432A5 (enExample)
JP2006522692A5 (enExample)
JP2015500805A5 (enExample)
JP2008081497A5 (ja) アントラセン誘導体、発光素子および発光装置
JP2008506698A5 (enExample)
WO2008006102A3 (en) Use of retro-aldol reaction to generate reactive vinyl ketone for attachment to anitibody molecules by michael addition reaction for use in immunostaining and immunotargeting